BlackRock Fund Advisors’s Aevi Genomic Medicine, Inc. GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | $4.59M | Buy |
886,435
+141,641
| +19% | +$734K | ﹤0.01% | 2970 |
|
|
2016
Q3 | $4.15M | Buy |
744,794
+111,981
| +18% | +$624K | ﹤0.01% | 2928 |
|
|
2016
Q2 | $3.51M | Buy |
632,813
+68,454
| +12% | +$380K | ﹤0.01% | 3008 |
|
|
2016
Q1 | $2.48M | Sell |
564,359
-31,988
| -5% | -$141K | ﹤0.01% | 3013 |
|
|
2015
Q4 | $3.59M | Buy |
596,347
+157,767
| +36% | +$950K | ﹤0.01% | 2993 |
|
|
2015
Q3 | $3.43M | Sell |
438,580
-5,160
| -1% | -$40.4K | ﹤0.01% | 2973 |
|
|
2015
Q2 | $2.72M | Buy |
443,740
+400,900
| +936% | +$2.46M | ﹤0.01% | 3117 |
|
|
2015
Q1 | $345K | Sell |
42,840
-2,912
| -6% | -$23.5K | ﹤0.01% | 3342 |
|
|
2014
Q4 | $232K | Buy |
45,752
+3,276
| +8% | +$16.6K | ﹤0.01% | 3446 |
|
|
2014
Q3 | $220K | Sell |
42,476
-3,094
| -7% | -$16K | ﹤0.01% | 3436 |
|
|
2014
Q2 | $354K | Buy |
45,570
+1,304
| +3% | +$10.1K | ﹤0.01% | 3287 |
|
|
2014
Q1 | $309K | Buy |
44,266
+9,455
| +27% | +$66K | ﹤0.01% | 3348 |
|
|
2013
Q4 | $209K | Buy |
34,811
+7,178
| +26% | +$43.1K | ﹤0.01% | 3434 |
|
|
2013
Q3 | $216K | Buy |
27,633
+2,178
| +9% | +$17K | ﹤0.01% | 3360 |
|
|
2013
Q2 | $97K | Buy |
+25,455
| New | +$97K | ﹤0.01% | 3532 |
|